Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TRISHA WISE-DRAPER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1306162367
CMS profile
1348174
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$7,777.55

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $6,710.00 1
Food and Beverage $586.50 7
Travel and Lodging $464.48 2
Education $16.57 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $7,445.25 7
AVEO Pharmaceuticals, Inc. $238.18 1
PFIZER INC. $77.55 2
E.R. Squibb & Sons, L.L.C. $16.57 1

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TRISHA WISE-DRAPER

NPI 1306162367 · CMS profile ID 1348174

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306162367?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306162367?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306162367?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1306162367?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $7,777.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $150.0011/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048436219 CMS
Merck Sharp & Dohme LLC $6,710.0011/20/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048436223 CMS
Merck Sharp & Dohme LLC $47.2211/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048253601 CMS
Merck Sharp & Dohme LLC $57.9111/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048253679 CMS
Merck Sharp & Dohme LLC $130.6411/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048253683 CMS
Merck Sharp & Dohme LLC $35.0011/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048253685 CMS
Merck Sharp & Dohme LLC $314.4811/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048253681 CMS
E.R. Squibb & Sons, L.L.C. $16.5706/12/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014971743 CMS
PFIZER INC. $41.8206/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049275312 CMS
PFIZER INC. $35.7306/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049317625 CMS
AVEO Pharmaceuticals, Inc. $238.1806/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049066903 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $262.13 3
PY2020 $590.34 6
PY2021 $1,500.00 1
PY2023 $7,777.55 11
PY2024 $14,141.99 15
PY2025 $19,550.73 20

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,091,344.57 191
PY2024 Recipient $1,142.00 1
PY2024 Principal investigator $1,113,643.03 103
PY2023 Principal investigator $647,553.50 123
PY2022 Principal investigator $951,903.86 101
PY2021 Principal investigator $1,602,672.00 113
PY2020 Recipient $2,270.00 3
PY2020 Principal investigator $2,351,551.68 45
PY2019 Principal investigator $1,957,016.08 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

123 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Epizyme, Inc. $5,130.00 12/28/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies No dispute reported 06/30/2026 980957813
Principal investigator 1 Epizyme, Inc. $3,333.33 12/28/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies No dispute reported 06/30/2026 980957821
Principal investigator 1 Epizyme, Inc. $3,600.00 12/28/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies No dispute reported 06/30/2026 980957827
Principal investigator 1 Epizyme, Inc. $585.00 12/28/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies No dispute reported 06/30/2026 980957833
Principal investigator 1 Epizyme, Inc. $17,640.00 12/28/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies No dispute reported 06/30/2026 980957839
Principal investigator 1 Epizyme, Inc. $1,689.00 12/28/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies No dispute reported 06/30/2026 980957845
Principal investigator 1 Epizyme, Inc. $1,982.25 12/28/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies No dispute reported 06/30/2026 980957853
Principal investigator 1 Ares Trading SA $3,030.00 12/20/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342529
Principal investigator 1 Ares Trading SA $4,050.00 12/20/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342537
Principal investigator 1 Ares Trading SA $270.00 12/20/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342543
Principal investigator 1 GlaxoSmithKline, LLC. $27,215.40 12/06/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER LLC
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 1006222041
Principal investigator 1 GlaxoSmithKline, LLC. $7,300.80 11/10/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER LLC
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 1006222029
Principal investigator 1 Alkermes, Inc. $4,688.29 10/25/2023 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 994094093
Principal investigator 1 Incyte Corporation $2,734.00 09/22/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040888229
Principal investigator 1 Incyte Corporation $365.00 09/22/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040888241
Principal investigator 1 Incyte Corporation $1,012.00 09/22/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040888255
Principal investigator 1 Incyte Corporation $2,734.00 09/22/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040888267
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $625.00 09/11/2023 Non-covered Recipient Entity
University Of Cincinnati
PhI/II TIGIT BiSpec combo (Nivo/NG CTLA4) safety & NSCLC expansion - A Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer No dispute reported 06/30/2026 1027456917
Principal investigator 1 Alkermes, Inc. $3,908.65 08/30/2023 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 994093863
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 08/30/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER LLC
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 1006222035
Principal investigator 1 GlaxoSmithKline, LLC. $2,700.00 08/30/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER LLC
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 1006222047
Principal investigator 1 GlaxoSmithKline, LLC. $2,700.00 08/30/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER LLC
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 1006222247
Principal investigator 1 GlaxoSmithKline, LLC. $1,012.00 08/30/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER LLC
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 1006222253
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 08/30/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER LLC
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 1006222261
Principal investigator 1 Ares Trading SA $948.00 07/26/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342281
Principal investigator 1 Ares Trading SA $948.00 07/26/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342289
Principal investigator 1 Ares Trading SA $616.80 07/26/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342295
Principal investigator 1 Ares Trading SA $1,008.00 07/26/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342301
Principal investigator 1 PFIZER INC. $4,375.00 07/26/2023 Non-covered Recipient Entity
University of Cincinnati
A TWOPART PHASE 1AB OPENLABEL MULTICENTER TRIAL EVALUATING PHARMACOKINETICS SAFETY AND EFFICACY OF PF 07284890 ARRY 461 IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT No dispute reported 06/30/2026 1046411081
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,050.00 07/25/2023 Non-covered Recipient Entity
University Of Cincinnati
2016-NIV-0647 Phase II investigation of adjuvant nivolumab after salvage resection in pts treated with definitive chemotherapy and radiation No dispute reported 06/30/2026 1027475205
Principal investigator 1 Seagen Inc. $1,350.00 07/25/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER
A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies No dispute reported 06/30/2026 995848121
Principal investigator 1 Seagen Inc. $31,376.00 07/25/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER
A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies No dispute reported 06/30/2026 995848131
Principal investigator 1 Janssen Research & Development, LLC $1,012.50 07/10/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
Phase II study to evaluate amivantamab in recurrent and metastatic adenoid cystic carcinoma No dispute reported 06/30/2026 986144255
Principal investigator 1 Merck Healthcare KGaA $8,448.95 07/06/2023 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) No dispute reported 06/30/2026 1051342039
Principal investigator 1 Epizyme, Inc. $1,500.00 06/29/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies No dispute reported 06/30/2026 980952029
Principal investigator 1 Epizyme, Inc. $1,500.00 06/29/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies No dispute reported 06/30/2026 980952035
Principal investigator 1 Epizyme, Inc. $1,013.00 06/29/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies No dispute reported 06/30/2026 980952041
Principal investigator 1 Ares Trading SA $628.00 06/23/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342443
Principal investigator 1 Ares Trading SA $439.60 06/23/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342451
Principal investigator 1 Ares Trading SA $628.00 06/23/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342493
Principal investigator 1 Incyte Corporation $6,700.00 05/26/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040888217
Principal investigator 1 Ares Trading SA $948.00 05/19/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342419
Principal investigator 1 Ares Trading SA $1,008.00 05/19/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342431
Principal investigator 1 Ares Trading SA $948.00 05/19/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342437
Principal investigator 1 Ares Trading SA $948.00 05/19/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342499
Principal investigator 1 Ares Trading SA $522.00 05/19/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342505
Principal investigator 1 Ares Trading SA $270.00 05/12/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342405
Principal investigator 1 Ares Trading SA $250.00 05/12/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342411
Principal investigator 1 Ares Trading SA $4,050.00 05/12/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342425
Principal investigator 1 Ares Trading SA $400.00 05/12/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342457
Principal investigator 1 Ares Trading SA $3,030.00 05/12/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342463
Principal investigator 1 GlaxoSmithKline, LLC. $82,673.07 05/09/2023 Non-covered Recipient Entity
UC HEALTH PHARMACY
AN OPEN-LABEL, PHASE II STUDY EVALUATING THE EFFICACY OF NIRAPARIB AND No dispute reported 06/30/2026 1006222003
Principal investigator 1 PFIZER INC. $625.00 05/06/2023 Non-covered Recipient Entity
University of Cincinnati
A TWOPART PHASE 1AB OPENLABEL MULTICENTER TRIAL EVALUATING PHARMACOKINETICS SAFETY AND EFFICACY OF PF 07284890 ARRY 461 IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT No dispute reported 06/30/2026 1046524307
Principal investigator 1 Ares Trading SA $528.00 05/03/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342399
Principal investigator 1 Ares Trading SA $948.00 05/03/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342469
Principal investigator 1 Ares Trading SA $948.00 05/03/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342475
Principal investigator 1 Ares Trading SA $948.00 05/03/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342481
Principal investigator 1 Ares Trading SA $948.00 05/03/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342487
Principal investigator 1 Seagen Inc. $425.25 04/25/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER
A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies No dispute reported 06/30/2026 995848033
Principal investigator 1 AstraZeneca UK Limited $14,633.59 04/20/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
A Phase 1b 2 Open Label Multicentre Study Assessing the Safety Tolerability Pharmacokinetics and Preliminary Anti tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and or Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 991141515
Principal investigator 1 AstraZeneca Pharmaceuticals LP $84,414.00 04/17/2023 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-label, Phase II Study of Durvalumab (MEDI4736) in combination with Cetuximab in Previously Treated Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 991131983
Principal investigator 1 GlaxoSmithKline, LLC. $5,474.95 04/16/2023 Non-covered Recipient Entity
UC HEALTH LABORATORY
Not supplied No dispute reported 06/30/2026 1006222017
Principal investigator 1 GlaxoSmithKline, LLC. $2,189.98 04/14/2023 Non-covered Recipient Entity
UC HEALTH LABORATORY
Not supplied No dispute reported 06/30/2026 1006222011
Principal investigator 1 GlaxoSmithKline, LLC. $41,495.04 04/14/2023 Non-covered Recipient Entity
UC HEALTH LABORATORY
Not supplied No dispute reported 06/30/2026 1006222023
Principal investigator 1 Incyte Corporation $57.96 04/10/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837575
Principal investigator 1 Incyte Corporation $199.32 04/10/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837587
Principal investigator 1 Incyte Corporation $11.20 04/10/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837599
Principal investigator 1 Incyte Corporation $945.00 04/05/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040888105
Principal investigator 1 Incyte Corporation $4,050.00 04/05/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040888119
Principal investigator 1 Incyte Corporation $625.00 04/05/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040888133
Principal investigator 1 Incyte Corporation $16,200.00 04/05/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040888145
Principal investigator 1 Incyte Corporation $1,620.00 04/05/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040888157
Principal investigator 1 Incyte Corporation $3,375.00 04/05/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040888169
Principal investigator 1 Incyte Corporation $13,500.00 04/05/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040888181
Principal investigator 1 Incyte Corporation $2,187.00 04/05/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040888193
Principal investigator 1 Incyte Corporation $3,375.00 04/05/2023 Covered Recipient Teaching Hospital
Univer.Of Cincinnati Med Center Llc
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040888205
Principal investigator 1 Merck Healthcare KGaA $5,069.25 03/16/2023 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) No dispute reported 06/30/2026 1051342019
Principal investigator 1 Janssen Research & Development, LLC $72,085.96 03/13/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
Phase II study to evaluate amivantamab in recurrent and metastatic adenoid cystic carcinoma No dispute reported 06/30/2026 986144251
Principal investigator 1 Incyte Corporation $4.26 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837197
Principal investigator 1 Incyte Corporation $0.32 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837211
Principal investigator 1 Incyte Corporation $2.08 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837225
Principal investigator 1 Incyte Corporation $4.04 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837237
Principal investigator 1 Incyte Corporation $40.76 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837249
Principal investigator 1 Incyte Corporation $35.08 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837261
Principal investigator 1 Incyte Corporation $74.13 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837273
Principal investigator 1 Incyte Corporation $19.38 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837287
Principal investigator 1 Incyte Corporation $3.40 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837299
Principal investigator 1 Incyte Corporation $0.90 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837311
Principal investigator 1 Incyte Corporation $1.55 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837323
Principal investigator 1 Incyte Corporation $20.26 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837337
Principal investigator 1 Incyte Corporation $42.00 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837349
Principal investigator 1 Incyte Corporation $20.42 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837361
Principal investigator 1 Incyte Corporation $25.02 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837374
Principal investigator 1 Incyte Corporation $32.50 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837388
Principal investigator 1 Incyte Corporation $42.88 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837399
Principal investigator 1 Incyte Corporation $44.64 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837407
Principal investigator 1 Incyte Corporation $20.42 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837415
Principal investigator 1 Incyte Corporation $25.02 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837423
Principal investigator 1 Incyte Corporation $20.42 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837431
Principal investigator 1 Incyte Corporation $20.42 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837439
Principal investigator 1 Incyte Corporation $25.02 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837447
Principal investigator 1 Incyte Corporation $20.42 03/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040837455
Principal investigator 1 GlaxoSmithKline, LLC. $3,284.97 03/03/2023 Non-covered Recipient Entity
UC HEALTH LABORATORY
Not supplied No dispute reported 06/30/2026 1006221997
Principal investigator 1 Eli Lilly and Company $190.00 02/23/2023 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER RANDOMIZED OPEN LABEL PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE ADVANCED KINASE INHIBITOR NAIVE RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) No dispute reported 06/30/2026 1038059373
Principal investigator 1 Ares Trading SA $948.00 02/22/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342307
Principal investigator 1 Ares Trading SA $812.40 02/22/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342359
Principal investigator 1 Merck Healthcare KGaA $6,683.00 01/26/2023 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) No dispute reported 06/30/2026 1051342025
Principal investigator 1 Merck Healthcare KGaA $2,561.22 01/26/2023 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) No dispute reported 06/30/2026 1051342033
Principal investigator 1 Ares Trading SA $794.40 01/20/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342319
Principal investigator 1 Ares Trading SA $948.00 01/20/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342325
Principal investigator 1 Ares Trading SA $1,008.00 01/20/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342331
Principal investigator 1 Ares Trading SA $948.00 01/20/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342339
Principal investigator 1 Ares Trading SA $948.00 01/20/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342345
Principal investigator 1 Ares Trading SA $1,008.00 01/20/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342351
Principal investigator 1 Ares Trading SA $1,008.00 01/20/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342365
Principal investigator 1 Ares Trading SA $948.00 01/20/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342371
Principal investigator 1 Ares Trading SA $948.00 01/20/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342381
Principal investigator 1 Ares Trading SA $948.00 01/20/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342387
Principal investigator 1 Ares Trading SA $948.00 01/20/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342393
Principal investigator 1 Eli Lilly and Company $69,566.00 01/10/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A MULTICENTER RANDOMIZED OPEN LABEL PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE ADVANCED KINASE INHIBITOR NAIVE RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) No dispute reported 06/30/2026 1038145347
Principal investigator 1 Seagen Inc. $4,432.05 01/10/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER
A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies No dispute reported 06/30/2026 995847855
Principal investigator 1 Seagen Inc. $4,750.78 01/10/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER
A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies No dispute reported 06/30/2026 995847863
Principal investigator 1 Ares Trading SA $853.20 01/04/2023 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 1051342313